A novel cell cycle inhibitor stalls replication forks and activates S phase checkpoint
Related Experiment Video
Updated: Jul 14, 2026

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
Vaidehi Krishnan1, Léon Dirick, Hong Hwa Lim
1Institute of Molecular and Cell Biology, Proteos, Singapore.
Abstract:
DNA replication checkpoint is activated in response to replication stresses. It maintains the integrity of stalled replication forks and prevents premature segregation of largely unreplicated chromosomes. In budding yeast, Mec1 and Rad53 kinases (homologous to mammalian ATM/ATR and Chk2 kinases, respectively) are the main effectors of this checkpoint control. Using a yeast based screen, we have identified a compound (named here ENA) which inhibits DNA replication and activates Mec1/Rad53 checkpoint. A brief exposure to this compound stops fork progression at or near replication origin and renders the forks incompetent to resume replication despite the presence of a functional checkpoint. ENA also inhibits DNA synthesis in mammalian cells leading to the activation of ATM/ATR pathway and the induction of apoptosis in a p53 independent manner. Interestingly, ENA acts as an effective anti-proliferative agent against a subset of cancer cell lines and as an anti-tumor agent against human xenografts in mice. Thus, ENA is a potent cell cycle inhibitor with conceivable therapeutic potential.
Insights
A novel compound, ENA, inhibits DNA replication and activates cell cycle checkpoints in yeast and human cells. This DNA replication inhibitor shows anti-proliferative and anti-tumor effects, suggesting therapeutic potential.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- The DNA replication checkpoint safeguards genome integrity during replication stress.
- Key kinases Mec1/Rad53 (yeast) and ATM/ATR/Chk2 (mammalian) mediate checkpoint responses.
- Understanding replication stress response is crucial for cancer therapy.
Purpose of the Study:
- To identify novel inhibitors of DNA replication.
- To investigate the mechanism of action of a newly identified compound, ENA.
- To evaluate the therapeutic potential of ENA in cancer models.
Main Methods:
- Yeast-based genetic screening to identify replication inhibitors.
- Biochemical assays to assess DNA synthesis inhibition and checkpoint activation.
- Cell-based assays in mammalian cells to study ATM/ATR pathway activation and apoptosis.
- In vivo studies using human xenograft models in mice.
Main Results:
- A compound, ENA, was identified that inhibits DNA replication and activates the Mec1/Rad53 checkpoint in yeast.
- ENA halts replication fork progression and prevents fork restart.
- ENA inhibits DNA synthesis in mammalian cells, activates ATM/ATR, induces p53-independent apoptosis, and exhibits anti-proliferative and anti-tumor activity.
Conclusions:
- ENA is a potent inhibitor of DNA replication and cell cycle progression.
- ENA activates DNA replication checkpoints and induces apoptosis through the ATM/ATR pathway.
- ENA demonstrates significant anti-cancer potential, warranting further investigation for therapeutic applications.
More Related Videos
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
11:23Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry
Published on: May 22, 2012
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...
The Cell Cycle Control System
The Cell Cycle Control System